title: CHOP-Bleo plus interferon for stage IV low-grade lymphoma.
abstract: BACKGROUND
  Alpha interferon (IFN) is an effective single agent for patients with low-grade lymphoma, but until 1982 had not been integrated with standard chemotherapy for these patients. Since relapse from complete remission (CR) is the rule for patients with advanced stage low-grade lymphoma, a maintenance IFN schedule was explored for patients in CR.
  
  
  METHODS
  From 1982-1987, 127 patients with stage IV low-grade lymphoma were treated with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo) for 9-18 mo. (median 13 mo.), followed by interferon alfa-n-1 (Wellferon) maintenance therapy for 24 mo. for CRs.
  
  
  RESULTS
  The overall response rate for the entire treatment program was 73% CR and 23% partial remission. The median follow up was 59 months. At 5 years, survival was 74%, failure-free survival (FFS) 47%, and FFS of CRs 60%. Compared to a group of 96 patients with similar pretreatment clinical features treated with CHOP-Bleo from 1972-1982, this represents a significant improvement for both overall FFS (p = 0.01) and FFS of CRs (P < 0.01). Toxicity from the IFN maintenance was generally acceptable, but even at the modest dose employed in this trial (3 x 10(6) U/m2 three times weekly), dose modification was required in more than 30% of patients, usually because of fatigue.
  
  
  CONCLUSIONS
  The integration of IFN and conventional chemotherapy is feasible and effective. Maintenance IFN prolongs remission duration for patients with stage IV low-grade lymphoma.
authors.affiliation: Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: P
authors.initials: P
authors.lastname: McLaughlin
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: F
authors.initials: F
authors.lastname: Swan
authors.forename: J E
authors.initials: JE
authors.lastname: Romaguera
authors.forename: S
authors.initials: S
authors.lastname: Taylor
authors.forename: M A
authors.initials: MA
authors.lastname: Rodriguez
authors.forename: W S
authors.initials: WS
authors.lastname: Velasquez
authors.forename: J R
authors.initials: JR
authors.lastname: Redman
authors.forename: J U
authors.initials: JU
authors.lastname: Gutterman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone